BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMS-986523 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMS-986523\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07223047-2412@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:BMS-986523: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:BMS-986523\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-986523 A
 lone and in Combination With Anti-Cancer Agents in Participants With Advan
 ced Solid Malignancies\nEstimated primary completion: 13 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bms-986523#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/bms-986523#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
